METHOD FOR PREPARING CELLS FOR TREATING DISEASES, METHOD FOR PROMOTING MIGRATION ABILITY OF CELLS, METHOD FOR PROMOTING PROLIFERATION ABILITY OF CELLS, AND CELLS OBTAINED BY THESE METHODS
An object of the present invention is to provide a method for obtaining cells having a high migration ability or cells having a high proliferation ability as cells having an increased therapeutic effect on diseases. The present invention is a method for preparing cells for treating diseases, a method for promoting a migration ability of cells, and a method for promoting a proliferative ability of cells, each of the methods comprising subjecting cells to ultrasonic treatment. The frequency of the ultrasonic treatment is preferably 30 kilohertz to 2.0 megahertz, and the cells are preferably mesenchymal stem cells. In addition, the present invention also includes cells obtained by the preparation method of the present invention.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
The purpose of the present invention is to provide a culture medium for immature eggs that is excellent in quality and safety and that is capable of efficiently maturing immature eggs with respect to immature eggs for vitro maturation-in vitro fertilization-embryo transfer method (IVM-IVF). The present invention is a composition that is for treating immature eggs and/or embryos (fertilized eggs) and that contains a serum-free mesenchymal stem cell culture medium. The treatment composition is suitably used as an immature egg culture agent, an embryo (fertilized egg) culture agent, an implantation adjuvant, an embryo transfer liquid or an implantation rate improver.
The purpose of the present invention is to provide sperm having high motility. The present invention is a composition for treating sperm that comprises medium for mesenchymal stem cells. This composition for treating sperm is used as a sperm preparing solution, a sperm diluting solution, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a solution for improving sperm motility, or a solution for retaining sperm fertilizing capabilities. Additionally, the medium for mesenchymal stem cells contained in the composition for treating sperm is preferably a serum-free medium.
The purpose of the present invention is to provide a preparation that is effective for maintaining or increasing a hair fibrous structural protein. Provided are a composition for maintaining or increasing a fibrous structural protein, a composition for maintaining or increasing skin elasticity, a composition for improving hair quality, and a composition for promoting the production of collagen, elastin, or hyaluronic acid, wherein each of the compositions contains a culture supernatant of microalgae and/or extracellular vesicles of microalgae.
This aqueous composition contains (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof, and has a pH of 6.0-9.0. The aqueous composition is housed in a dispensing container having a filter containing a hydrophilic material.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61J 1/05 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour recueillir, stocker ou administrer du sang, du plasma ou des liquides à usage médical
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
The present invention relates to providing a novel compound, specifically a 1,3,5-triazine derivative and salt thereof, which has a suitable ultraviolet absorption action, and to an ultraviolet absorbent and external skin agent using the same. The present invention is the 1,3,5-triazine derivative or salt thereof represented by general formula (I), etc. (In the general formula, G1, G2, and G3each independently represent hydrogen, a straight or branched chain alkyl group, etc. having 1-12 carbon atoms which may be substituted, or -X-Z-Y. However, at least two of G1, G2, and G3may be -X-Z-Y, which may be identical or different from each other. X is O, N, or S. Y is a sulfonic acid group, a hydroxyl group, or a carboxyl group, etc., or a group corresponding to a salt thereof. Z is a straight or branched chain alkyl group, etc. having 1-8 carbon atoms. R1, R2, and R3 each independently represent a straight or branched chain alkyl group, etc. having 1-4 carbon atoms, and l, m, and n each independently represent an integer from 0 to 4.)
Provided are a cleansing composition and the like having excellent sebum cleansing properties. Specifically provided are a cleansing composition comprising components (A), (B) and (C) as mentioned below, a cleaning composition for deodorant purposes, and a method for removing an aging odor by cleansing using a cleansing composition. (A) An anionic cleansing component. (B): A component (B1) and/or a component (B2) as mentioned below. (B1) A monoester of a C6-12 fatty acid and a C1-6 polyhydric alcohol. (B2) At least one component selected from the group consisting of fatty acid alkanolamides, coconut oil fatty acid polyoxyethylene glyceryls, and polyoxyethylene alkyl ethers. (C) A water-soluble polymer.
A61K 8/81 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons insaturées carbone-carbone
The present invention pertains to an ophthalmic composition containing (A) at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 1000 to 20000 and a salt thereof, and (B) a fat-soluble component.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present invention pertains to an ophthalmic composition containing (A) at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 1000 to 20000 and a salt thereof, and (B) at least one selected from the group consisting of water-soluble vitamins, amino acids, and salts thereof.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
The purpose of the present invention is to provide an external-use composition with which aroma is maintained for a long period of time after application to the skin. Another purpose of the present invention is to provide a method with which it is possible, in relation to an external-use composition, to provide sufficient fragrance after application to the skin, and to maintain the fragrance for a long period of time. The present invention is an external-use composition containing (A) a hydroxy fatty acid or a salt thereof having 10 or more carbon atoms and a hydroxy group at the 4-position or 5-position, and (B) one or more components selected from the group consisting of (b-1) 1-6-valent alkyl alcohols, (b-2) amphiphilic esters, (b-3) phenol derivatives, and (b-4) cationized polymers.
The purpose of the present invention is to provide a pharmaceutical preparation that effectively activates hair dermal papilla cells. Provided is a composition for activating hair dermal papilla cells, a composition for promoting hair growth or for hair restoration, a composition for improving hair quality, and a composition for promoting production of FGF-2, FGF-7, or VEGF, the compositions containing microalgae culture supernatant and/or microalgae extracellular vesicle.
The present invention provides a novel preparation which has an excellent lipolysis-promoting effect, an excellent visceral fat and body fat loss effect, an excellent weight loss effect, and an excellent BMI improvement effect. Another purpose of the present invention is to provide a novel preparation which has an excellent insulin resistance amelioration effect, an excellent cholesterol level reduction effect, and the like. The present invention is an internal composition which contains glyasperin B and which is used for at least one of lipolysis, fat burning, fat consumption support, BMI improvement, BMI reduction support, abdominal fat loss, visceral fat loss, body fat loss, waist circumference reduction, insulin resistance amelioration, and LDL cholesterol level reduction. The internal composition according to the present invention is preferably used by adults who have a BMI of at least 23 kg/m2but less than 30 kg/m2and adults who have a visceral fat area of at least 100 cm2.
To provide an oil-based solid composition for external use having excellent stability. An oil-based solid composition for external use is prepared that comprises: (A) an oily component with a melting point of 55° C. or higher; (B) a polyhydric alcohol; and (C) an acrylic acid-based water-soluble polymer.
A61K 8/81 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons insaturées carbone-carbone
A61K 8/92 - Huiles, graisses ou ciresLeurs dérivés, p. ex. produits d'hydrogénation
A61Q 19/00 - Préparations pour les soins de la peau
Provided is a stable emulsion composition. Prepared is an emulsion composition comprising: (A) an oily component; (B) 40% by mass or more of one or more selected from the group consisting of polyhydric alcohols having 3 to 5 carbon atoms and polyethylene glycol; (C) one or more selected from the group consisting of polyacrylamide compounds and polyvinylpyrrolidone; (D) 0%-15% by mass of water; and (E) at least one selected from PEG -20 phytosterol, polyoxyethylene arachyl ether, glyceryl behenate, and polyglyceryl-6 octastearate.
A61K 8/81 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons insaturées carbone-carbone
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
32 - Bières; boissons non alcoolisées
35 - Publicité; Affaires commerciales
43 - Services de restauration (alimentation); hébergement temporaire
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemicals; glue and adhesives for industrial purposes; plant
growth regulating preparations; fertilizers; ceramic
glazings; priming putty; higher fatty acids; alkaline
metals; alkaline-earth metals; non-metallic minerals;
chemical compositions for developing and printing
photographs; reagent paper [not for medical purposes];
artificial sweeteners for industrial purposes; flour and
starch for industrial purposes; plastics [raw materials];
groundwood pulp or chemical pulps for manufacturing
purposes; yeast nutrients for industrial purposes; yeast for
scientific purposes; microorganisms for scientific,
industrial or agricultural use; culture medium for
photosynthetic bacteria; cultured microorganisms (not for
medical and veterinary use); bacterial preparations, other
than for medical and veterinary use; bacteriological
preparations for acetification; bacteriological preparations
other than for medical and veterinary use; gram-negative
bacteria, escherichia coli strains, and other cultured
microorganisms (not for medical and veterinary use);
cellulolytic microorganisms (not for medical and veterinary
use). Antistatic preparations for household purposes; de-greasing
preparations for household purposes; rust removing
preparations; stain removing benzine; fabric softeners for
laundry use; laundry bleach; adhesives for affixing false
hair; laundry starch; seaweed gelatine for laundry use
[funori]; adhesives for affixing false eyelashes; breath
freshening preparations; deodorants for animals; paint
stripping preparations; shoe cream; shoe black [shoe
polish]; polishing preparations; soaps and detergents;
dentifrices; cosmetics; perfumes and flavourings for
beverages [essential oils]; perfumes and food flavourings
[essential oils]; incense; abrasive paper [sandpaper];
abrasive cloth; abrasive sand; artificial pumice stone;
polishing paper; false nails; false eyelashes. Pharmaceutical preparations; reagent paper for medical
purposes; oiled paper for medical purposes; adhesive tapes
for medical purposes; drug delivery agents in the form of
edible wafers for wrapping powdered pharmaceuticals; gauze
for dressings; empty capsules for pharmaceuticals;
eyepatches for medical purposes; ear bandages; menstruation
bandages; menstruation tampons; sanitary napkins; sanitary
panties; absorbent cotton; adhesive plasters; bandages for
dressings; liquid bandages; breast-nursing pads; cotton
swabs for medical use; dental materials; diapers; diaper
covers; fly catching paper; mothproofing paper; lacteal
flour for babies; dietary supplements for human beings;
dietetic beverages adapted for medical purposes; dietetic
foods adapted for medical purposes; beverages for babies;
food for babies; dietary supplements for animals; semen for
artificial insemination; stem cells for medical,
pharmaceutical or veterinary use; stem cells for
regenerative medicine, medicine or veterinary use; stem
cells (only for medical and veterinary use); diagnostic
reagents for clinical or medical laboratory use; diagnostic
media for bacteriological cultures; microorganism culture
media for medical use; cell culture media for medical or
veterinary use; serums; serotherapeutic medicines; fumigants
[only for agricultural purposes]; fungicides [only for
agricultural purposes]; rodenticides [only for agricultural
purposes]; insecticides [only for agricultural purposes];
herbicides [weedkillers]; insect-repellents [only for
agricultural purposes]; antiseptics [only for agricultural
purposes]. Finger guards for medical purposes; sanitary masks;
pacifiers for babies; ice bag pillows for medical purposes;
triangular bandages; support bandages; surgical catguts;
feeding cups for medical purposes; dropping pipettes for
medical purposes; teats; medical ice bags; medical ice bag
holders; baby bottles; nursing bottles; contraceptives,
non-chemical; artificial tympanic membranes; prosthetics or
fillings materials, not for dental use; ear plugs for
swimmers; ear plugs for sleeping; ear plugs for
soundproofing; facial equipment using ultrasonic waves for
commercial use; esthetic massage apparatus for commercial
use; medical apparatus and instruments; facial equipment
using ultrasonic waves for household purposes; electric
massage apparatus for household purposes; gloves for medical
purposes; urinals for medical purposes; bed pans; ear picks. Beer; carbonated drinks [refreshing beverages]; fruit
juices; vegetable juices [beverages]; extracts of hops for
making beer; whey beverages. Advertising and publicity services; promoting the goods and
services of others through the administration of sales and
promotional incentive schemes involving trading stamps;
business management analysis or business consultancy;
business management; marketing research or analysis;
providing information concerning commercial sales;
employment agency services; auctioneering; import-export
agencies; arranging newspaper subscriptions; shorthand
services; transcription; document reproduction; office
functions, namely filing, in particular documents or
magnetic tapes; compilation of information into computer
databases; providing business assistance to others in the
operation of data processing apparatus namely, computers,
typewriters, telex machines and other similar office
machines; reception services for visitors in buildings
[office functions]; publicity material rental; rental of
photocopying machines; providing commercial information and
advice for consumers in the choice of products and services;
providing employment information; providing information
about newspaper articles being news clipping services;
rental of vending machines; retail services or wholesale
services for foods and beverages; retail services or
wholesale services for carbonated drinks [refreshing
beverages] and non-alcoholic fruit juice beverages; retail
services or wholesale services for tea, coffee and cocoa;
retail services or wholesale services for processed food;
retail or wholesale of pharmaceutical, veterinary, sanitary
preparations and medical aids; retail services or wholesale
services for pharmaceutical, veterinary and sanitary
preparations and medical supplies; retail services or
wholesale services for cosmetics, toiletries, dentifrices,
soaps and detergents. Providing temporary accommodation; accommodation bureaux
services [hotels, boarding houses]; providing foods and
beverages; boarding for animals; preschooler and infant care
at daycare centers; retirement home; rental of meeting
rooms; rental of facilities for exhibitions; rental of futon
and quilts; rental of pillows; rental of blankets; rental of
electric hot plates for household purposes; rental of
electric toasters for household purposes; rental of
microwave ovens for household purposes; rental of cooking
equipment for industrial purposes; rental of kitchen sinks
incorporating integrated worktops for commercial use; rental
of kitchen sinks for commercial use; rental of non-electric
cooking heaters for household purposes; rental of kitchen
sinks incorporating integrated worktops for household
purposes; rental of kitchen sinks for household purposes;
rental of dishes; rental of curtains; rental of furniture;
rental of wall hangings; rental of floor coverings; rental
of towels for hotels; rental of towels for restaurants;
rental of towels. Beauty salons; barbershops; providing bath houses; garden
tree planting; garden or flower bed care; fertilizer
spreading; weed killing; vermin exterminating [for
agriculture, aquaculture, horticulture or forestry];
landscape design; massage and therapeutic shiatsu massage;
chiropractic; moxibustion; treatment for dislocated joints,
sprain, bone fractures [judo- seifuku]; bodywork therapy;
acupuncture; providing medical information; physical
examination; dietary and nutritional guidance; animal
breeding; veterinary services; beautification for animals;
nursing care; rental of potted plants; farming equipment
rental; rental of medical apparatus and instruments; rental
of fishing equipment and instruments; rental of apparatus
and instruments for use in beauty salons or barbers' shops;
rental of lawnmowers.
19.
PROPHYLACTIC/THERAPEUTIC AGENT FOR PREGNANCY-INDUCED HYPERTENSION
NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (Japon)
MEDICAL CORPORATION SANEIKAI (Japon)
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japon)
ROHTO PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Matsumoto Kunio
Imamura Ryu
Kato Yukio
Masuo Yusuke
Mizutani Shigehiko
Kajiyama Hiroaki
Yoshihara Masato
Abrégé
The present invention addresses the problem of providing a prophylactic and/or therapeutic agent for hypertensive disorders of pregnancy, which has a physical property or a molecular weight that inhibits the passage through the placental barrier, has a pharmacological activity that mimics the original physiological function of the placenta and therefore has fewer adverse side effects, is safe for a mother body and a fetus, is stable for a long period, and can exert the efficacy thereof in vivo for a long period. The present invention is a prophylactic/therapeutic agent for pregnancy-induced hypertension, which contains aminopeptidase A (APA) as an active ingredient, the prophylactic/therapeutic agent being characterized in that the APA is bound to an immunoglobulin Fc region through a peptide linker.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japon)
ROHTO PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Yoshihara,masato
Kajiyama,hiroaki
Enomoto,atsushi
Abrégé
It has been difficult to quantify the degree of epithelial-mesenchymal transition of peritoneal mesothelial cells from cell morphology, and no biomarker specific for epithelial-mesenchymal transition of mesothelial cells has been known. Provided is a method for screening a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells, the method including the following steps: (a) a step for treating mesothelial cells with a candidate substance; (b) a step for determining the expression or activity level of LRRN4 (leucine rich repeat neuronal 4) in the mesothelial cells; and (c) a step for, when the expression or activity level of LRRN4 is increased as compared with the level before the treatment, then selecting the candidate substance as a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
21.
SKIN PERMEATION PROMOTER FOR HYALURONIC ACID, SKIN PERMEATION PROMOTION METHOD FOR HYALURONIC ACID, SKIN PERMEATION INHIBITOR FOR HYALURONIC ACID, AND SKIN PERMEATION INHIBITION METHOD FOR HYALURONIC ACID
The present invention addresses the problem of controlling the skin's permeability of hyaluronic acid. Specifically, a purpose of the present invention is to provide a technology for promoting or inhibiting the skin's permeability of a specific hyaluronic acid, in a skin topical composition. Another purpose of the present invention is to provide a skin topical composition that, by controlling the skin's permeability of hyaluronic acid, provides excellent feelings of use such as feeling of moistness, feeling of plumpness, permeation feeling, skin compatibility, and feeling of wetness. To solve the problem, the present invention is a skin penetration promoter that is for (B) a hyaluronic acid having a weight average molecular weight of at least 1,000,000, a hyaluronic acid derivative, or a salt thereof, and that comprises (A) a hyaluronic acid having a weight average molecular weight of at most 600,000, a hyaluronic acid derivative, or a salt thereof. The present invention is also a skin penetration inhibitor that is for (D) a hyaluronic acid having a weight average molecular weight of at most 100,000, a hyaluronic acid derivative, or a salt thereof, and that comprises (C) a hyaluronic acid having a weight average molecular weight of at least 600,000, a hyaluronic acid derivative, or a salt thereof.
The present invention relates to an ophthalmic composition containing a Janus kinase inhibitor, the ophthalmic composition being accommodated in a container sterilized by a means other than an electron beam.
The present invention relates to an aqueous composition containing: (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof; and (B) a chelating agent.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
The purpose of the present invention is to provide a medium for culture excellent in growth of mesenchymal stem cells. The present invention is a mesenchymal stem cell growth promoter containing 16:0 lysophosphatidic acid, a derivative of 16:0 lysophosphatidic acid, and/or a salt thereof. The mesenchymal stem cell growth promoter of the present invention preferably also contains 18:1 lysophosphatidic acid, a derivative of 18:1 lysophosphatidic acid, and/or a salt thereof. The present invention also includes a medium for mesenchymal stem cells that contains16:0 lysophosphatidic acid, a derivative of 16:0 lysophosphatidic acid, and/or a salt thereof.
The present disclosure addresses the problem of providing a liquid agent container that readily assumes a structure corresponding to the viscosity of a liquid agent. A liquid agent container (1) comprising: a hollow cylindrical nozzle (2) that has a discharge port (20) at the distal end thereof; a ball valve (3) that is held within the nozzle (2); and a container body (4) that is connected to the nozzle (2) and is flexible, a liquid agent (L1) being accommodated in the container body (4). The nozzle (2) has an abutment surface (21) that abuts the ball valve (3) across the circumferential direction, and a holding part (22) that holds the ball valve (3) in a state of abutting the abutment surface (21). The abutment surface (21) is provided with a groove (5) that links the discharge port (20) and a space inside the nozzle (2), the space being closer to the container body (4) than the abutment surface (21).
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Absorbent cotton; adhesive plasters; adhesive tapes for medical purposes; bandages for dressings; beverages for babies; breast-nursing pads; collyrium; cotton swabs for medical use; diaper covers; disinfectants for contact lenses; ear bandages; empty capsules for pharmaceuticals; eye drops; eyepatches for medical purposes; fly catching paper; food for babies; gauze for dressings; lacteal flour for babies; liquid bandages; medicated eye-washes; menstruation bandages; menstruation tampons; mothproofing paper; reagent paper for medical purposes; sanitary napkins; sanitary panties; solutions for contact lenses
(2) Pharmaceutical preparations; Cleaning stock solution for contact lenses that increases moisture; Rinsing, cleaning, preserving solution for contact lenses; Eyewashes that are used while wearing contact lenses; Eye drops for use while wearing contact lenses; Contact lens solutions for cleaning, disinfecting and preserving purposes; Oiled paper for medical purposes; Dental materials; Diapers; Dietary supplements for humans; Dietetic beverages adapted for medical purposes; Dietetic food adapted for medical purposes; Dietary supplements for animals; Semen for artificial insemination;
Provided is an oil-in-water external composition having excellent suppression of unpleasant odor. An oil-in-water external composition comprising (A) 5% by mass or more non-polar oil, (B) a polar oil and (C) 8% by mass or more ultraviolet scattering agent.
A61Q 17/00 - Préparations protectricesPréparations employées en contact direct avec la peau pour protéger des influences extérieures, p. ex. des rayons du soleil, des rayons X ou d'autres rayons nuisibles, des matériaux corrosifs, des bactéries ou des piqûres d'insectes
28.
COMPOSITION FOR ALLEVIATING FATIGUE OR PROMOTING RECOVERY FROM FATIGUE
The purpose of the present invention is to provide a composition that contains a component that can be used in the beverage/food field and is effective on fatigue. The present invention provides a composition for alleviating fatigue or promoting the recovery from fatigue, a composition for improving exercise capabilities, a composition for enhancing physical strength, a composition for reducing blood lactic acid level, or a composition for inhibiting lactic acidosis, which contains a globin protein decomposition product. The present invention also provides a composition for alleviating fatigue or promoting the recovery from fatigue, a composition for improving exercise capabilities, a composition for enhancing physical strength, a composition for reducing blood lactic acid level, or a composition for inhibiting lactic acidosis, which contains a tetrapeptide represented by the formula: Val-Val-Tyr-Pro.
Provided is a novel composition having excellent ultraviolet ray absorption capability In the present invention, the following is prepared: an emulsified topical composition containing (C) diethylamino hydroxybenzoyl hexyl benzoate, and (A) porous silica including an ultraviolet absorber, where the average particle diameter of the porous silica is 1.4 to 40 μm, and the ultraviolet absorber included in the (A) component is solid at 25°C; or an emulsified topical composition containing (A2) porous silica including an ultraviolet absorber and (B) a non-ionic surfactant, where the average particle diameter of the porous silica is 1.4 to 40 μm, and the porous silica includes an ultraviolet absorber that is solid at 25°C.
A61K 8/46 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant du soufre
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61Q 17/04 - Préparations topiques pour faire écran au soleil ou aux radiationsPréparations topiques pour bronzer
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antistatic preparations for household purposes; de-greasing preparations for household purposes; rust removing preparations; stain removing benzine; fabric softeners for laundry use; laundry bleach; adhesives for affixing false hair; laundry starch; seaweed gelatine for laundry use [funori]; adhesives for affixing false eyelashes; breath freshening preparations; deodorants for animals; paint stripping preparations; shoe cream; shoe black [shoe polish]; polishing preparations; soaps and detergents; dentifrices; cosmetics; perfumes and flavourings for beverages [essential oils]; perfumes and food flavourings [essential oils]; incense; abrasive paper [sandpaper]; abrasive cloth; abrasive sand; artificial pumice stone; polishing paper; false nails; false eyelashes.
(2) Pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for human beings; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals; semen for artificial insemination; stem cells for medical, pharmaceutical or veterinary use; stem cells for regenerative medicine, medicine or veterinary use; stem cells (only for medical and veterinary use); diagnostic reagents for clinical or medical laboratory use; diagnostic media for bacteriological cultures; microorganism culture media for medical use; cell culture media for medical or veterinary use; serums; serotherapeutic medicines; fumigants [only for agricultural purposes]; fungicides [only for agricultural purposes]; rodenticides [only for agricultural purposes]; insecticides [only for agricultural purposes]; herbicides [weedkillers]; insect-repellents [only for agricultural purposes]; antiseptics [only for agricultural purposes].
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Antistatic preparations for household purposes; de-greasing preparations for household purposes; rust removing preparations; stain removing benzine; fabric softeners for laundry use; laundry bleach; adhesives for affixing false hair; laundry starch; seaweed gelatine for laundry use (funori); adhesives for affixing false eyelashes; breath freshening preparations; deodorants for animals; paint stripping preparations; shoe cream; shoe black (shoe polish); polishing preparations; soaps and detergents; dentifrices; cosmetics; perfumes and flavourings for beverages (essential oils); perfumes and food flavourings (essential oils); incense; abrasive paper (sandpaper); abrasive cloth; abrasive sand; artificial pumice stone; polishing paper; false nails; false eyelashes Pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for human beings; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals; semen for artificial insemination; stem cells for medical, pharmaceutical or veterinary use; stem cells for regenerative medicine, medicine or veterinary use; stem cells (only for medical and veterinary use); diagnostic reagents for clinical or medical laboratory use; diagnostic media for bacteriological cultures; microorganism culture media for medical use; cell culture media for medical or veterinary use; serums; serotherapeutic medicines; fumigants (only for agricultural purposes); fungicides (only for agricultural purposes); rodenticides (only for agricultural purposes); insecticides (only for agricultural purposes); herbicides (weedkillers); insect-repellents (only for agricultural purposes); antiseptics (only for agricultural purposes)
32.
METHOD FOR PRODUCING GEL-LIKE WOUND HEALING AGENT, GEL-LIKE WOUND HEALING AGENT, AND AUTOLOGOUS PLATELET-RICH PLASMA GEL PREPARATION KIT FOR WOUND HEALING
The purpose of the present invention is to provide a treatment method and therapeutic agent by which a sufficient effect can be obtained even with regard to a wound or the like for which an improvement trend is not observed with existing treatment methods. The present invention pertains to a method for producing a gel-like wound healing agent, the method comprising a feature of mixing an effective amount of a platelet-rich plasma (A), 150-300 mg/mL of an ascorbic acid solution (B), 1.0-3.0 wt% of a calcium chloride solution (C), and thrombin (D), a mixing ratio of the platelet-rich plasma (A) and the ascorbic acid solution (B) being 1.0-3.0 mL of the ascorbic acid solution (B) per 8.0 mL of the platelet-rich plasma (A), a mixing ratio of the platelet-rich plasma (A) and the calcium chloride solution (C) being 1.0-3.0 mL of the calcium chloride solution (C) per 8.0 mL of the platelet-rich plasma (A), and the amount of thrombin (D) being 500-2000 U per 8.0 mL of the platelet-rich plasma (A).
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
The purpose of the present invention is to provide an excellent infertility treatment with which it is possible to increase the implantation rate of an embryo (fertilized egg) by improving the uterine environment. The present invention is a uterine treatment composition containing a mesenchymal stem cell culture supernatant, and is used as a uterine environment-improving agent, an implantation aid, an embryo transplant liquid, a sperm transplantation liquid, or an implantation rate-improving agent. The mesenchymal stem cells are preferably derived from adipose tissue, umbilical cord tissue, or bone marrow tissue.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
34.
BIOMARKER FOR USE IN PREDICTION OF OCCURRENCE OF ACNE VULGARIS, PREDICTION OF SEVERITY AND DETERMINATION OF SEVERITY
Disclosed is a biomarker for use in the prediction of the occurrence and the severity of acne vulgaris, and in the determination of the severity of acne vulgaris.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The purpose of the present invention is to provide sperm having high motility. The present invention is a sperm treatment composition that contains an exosome. A sperm treatment composition according to the present invention is used as a sperm preparation solution, a sperm diluent, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a sperm motility improving solution, or a sperm fertility maintaining solution.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
The purpose of the present invention is to produce and provide a burdock seed oil-containing composition that is excellent in stability. The present invention relates to a composition containing (A) burdock seed oil and (B) triethyl citrate and containing 1 to 7.5 mass% of arctigenin derived from the component (A), and a method for producing the same.
Provided is a system for determining the possibility of glaucoma without a large-scale measurement of a myoelectric potential of the heart. This glaucoma determination system (1) comprises a processing unit (112) which acquires index data pertaining to the blood flow of a subject, determines, on the basis of the acquired index data, the possibility of glaucoma pertaining to an eyeball of the subject, and outputs information pertaining to the determined possibility of glaucoma.
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
A61B 3/12 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour examiner le fond de l'œil, p. ex. ophtalmoscopes
38.
THERAPEUTIC AGENT FOR RENAL DISEASE AND RENAL FUNCTION-IMPROVING AGENT
The purpose of the present invention is to provide a novel therapeutic agent for renal disease. The present invention is a therapeutic agent for renal disease containing a mesenchymal stem cell culture supernatant. The mesenchymal stem cell culture supernatant is preferably a culture supernatant obtained from the cultivation of mesenchymal stem cells derived from adipose tissue, umbilical tissue, or bone marrow tissue. In addition, the mesenchymal stem cell culture supernatant is preferably obtained from the cultivation of mesenchymal stem cells in a culture medium containing at least one substance selected from the group consisting of EGF, bFGF, albumin, transferrin, and insulin.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
The purpose of the present invention is to provide a composition that improves conditions related to ocular blood flow by evaluating effects on ocular blood flow. Provided is a composition for improving and/or maintaining ocular blood flow, said composition containing Zingiber officinale and/or an extract thereof. Also provided are a composition for maintaining the health of vascular tissues in the ocular region, a composition for anti-aging of the ocular region, a composition for improving and/or maintaining the health of the ocular region, visual field narrowing, visual field defects or the appearance or expansion of a dark spot, and a composition for treating and/or preventing ocular circulation disorders, each composition containing the aforesaid ingredient.
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
Provided is a composition comprising ginger and lutein and/or crocetin, wherein decomposition over time of the components contained in the composition is suppressed. Also provided is a method for suppressing decomposition of the composition components and a method for producing the composition. The composition comprises: (A) one or more selected from the group consisting of Zingiber officinale var. Rubra and extracts thereof; and (B) one or more selected from the group consisting of lutein and crocetin.
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A23L 19/00 - Produits à base de fruits ou de légumesLeur préparation ou leur traitement
42.
SYSTEM FOR DETERMINING DEPRESSION RISK USING FUNDUS IMAGE, MACHINE LEARNING MODEL GENERATION DEVICE, DEPRESSION RISK DETERMINATION DEVICE, AND DEPRESSION RISK DETERMINATION METHOD
Provided is a depression risk determining system with which it is possible to determine the risk of depression from a fundus image. The system for determining depression risk according to the present invention comprises: a machine learning model generation device that generates a trained model for determining the risk of depression; and a depression risk determination device that determines the risk of depression by using the trained model generated by the machine learning model generation device. The machine learning model generation device includes a data acquisition unit that acquires at least inquiry data for training and a fundus image for training, and a machine learning model generation unit that generates a trained model. The depression risk determination device includes a determination data acquisition unit that acquires a fundus image used for determination, a depression risk determination unit that inputs at least the fundus image used for determination to the trained model to thereby output a prediction score indicating depression risk, and a determination result output unit that outputs the determination results of depression risk on the basis of the prediction score.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
The present invention relates to an ophthalmic composition containing tramadol or a salt thereof. This ophthalmic composition has a pH of 4.0 to 6.8 and is stored in a container in which a portion of or all of the part thereof contacting this ophthalmic composition is formed from plastic.
The present invention relates to an ophthalmic composition which contains tramadol or a salt thereof and does not substantially contain a preservative agent.
The present invention relates to an ophthalmic composition containing tramadol or a salt thereof, wherein the ophthalmic composition is accommodated in a container of which part or all of a portion coming into contact with the ophthalmic composition is formed from a plastic, and the container is subjected to a sterilization treatment by a means other than an electron beam.
A61K 47/08 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'oxygène
The objective of the present invention is to provide a biomarker for use in determination of skin aging, comprising a protein or a fragment thereof. Alternatively, the objective of the present invention is to provide a method for determining skin aging in a subject, characterized in measuring a protein or a fragment thereof in a blood sample of the subject. Yet alternatively, the objective of the present invention is to provide a method for screening a skin aging improvement substance, characterized in studying an expression level of or a concentration change in a protein or a fragment thereof in a blood sample of a subject before and after intake of a test substance by the subject. The present invention is a biomarker for use in determination of skin aging, comprising a protein selected from the group consisting of: osteomodulin (OMD); chondroadherin (CHAD); collagen type XI alpha 2 chain (COL11A2); leucine-rich repeat-containing protein 15 (LRRC15); glycoprotein hormones alpha chain/choriogonadotropin subunit beta 3/choriogonadotropin subunit beta 7 (CGA/CGB3/CGB7); lutropin subunit beta (LHB); glycoprotein hormones alpha chain/lutropin subunit beta (CGA/LHB); and glycoprotein hormones alpha chain/follitropin subunit beta (CGA/FSHB), or a fragment thereof.
C12N 15/12 - Gènes codant pour des protéines animales
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
49.
COMPOSITION FOR AMELIORATING UNPLEASANT STATE CAUSED BY MENSTRUATION
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japon)
LINK GENOMICS, INC. (Japon)
ROHTO PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Katabuchi, Hidetaka
Honda, Ritsuo
Niwa, Shinichiro
Kitadai, Eri
Mizunuma, Hidemi
Arita, Harumasa
Abrégé
The object of the present invention is to provide: a composition for ameliorating an unpleasant state caused by menstruation, which is effective against discomfort occurring in women in the period from the first menstruation to menopause, particularly strong discomfort occurring in young women, has been sufficiently experienced as a foodstuff and has an anti-EMT activity; and a functional food containing the composition. A composition for ameliorating an unpleasant state caused by menstruation is prepared, which comprises at least one component selected from the group consisting of black rice, cherry blossom, and extracts thereof.
A first invention pertains to an aqueous composition that contains (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof, and that is housed in a container in which all or a portion thereof in contact with the aqueous composition is formed of a resin containing a polyolefin. A second invention pertains to an aqueous composition containing (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof, and (B) a chelating agent.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof (A) and at least one selected from the group consisting of citric acid, phosphoric acid, and a salt thereof (B).
The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof (A) and at least one selected from the group consisting of edetic acid, creatinine, and a salt thereof (B).
The present invention aims to provide a prophylactic and/or therapeutic agent for diabetes that is highly effective on diabetes developed as a side effect from immune checkpoint inhibitors and has a certain effect on many patients. The present invention is a therapeutic agent for diabetes comprising mesenchymal stem cells. The prophylactic and/or therapeutic agents for diabetes of the present invention are suitably used particularly for diabetes caused by immune checkpoint inhibitors and diabetes caused by anti-PD-1 antibody or anti-PD-L1 antibody.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
54.
COMPOSITION FOR AMELIORATING UNPLEASANT STATE CAUSED BY MENSTRUATION
The purpose of the present invention is to provide: a composition for ameliorating an unpleasant state related to menstruation, the composition being effective for an unpleasant feeling felt by females from first menstruation to menopause, in particular, a strongly unpleasant feeling felt by young females, the composition having anti-EMT activity and being commonly consumed as foodstuff; and a functional food containing said composition. The present invention prepares a composition for ameliorating an unpleasant state related to menstruation, containing plant-based polyphenol.
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
A61P 1/06 - Antispasmodiques, p. ex. médicaments pour le traitement des coliques, des dyskinésies œsophagiennes
A61P 1/08 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des nausées, du mal des transports ou des vertigesAntiémétiques
A61P 5/24 - Médicaments pour le traitement des troubles du système endocrinien des hormones sexuelles
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
METHOD FOR PREPARING CELLS FOR TREATING DISEASES, METHOD FOR PROMOTING MIGRATION ABILITY OF CELLS, METHOD FOR PROMOTING PROLIFERATION ABILITY OF CELLS, AND CELLS OBTAINED BY THESE METHODS
An object of the present invention is to provide a method for obtaining cells having a high migration ability or cells having a high proliferation ability as cells having an increased therapeutic effect on diseases. The present invention is a method for preparing cells for treating diseases, a method for promoting a migration ability of cells, and a method for promoting a proliferative ability of cells, each of the methods comprising subjecting cells to ultrasonic treatment. The frequency of the ultrasonic treatment is preferably 30 kilohertz to 2.0 megahertz, and the cells are preferably mesenchymal stem cells. In addition, the present invention also includes cells obtained by the preparation method of the present invention.
The present invention provides a method for evaluating the efficacy of a physical or chemical means on the treatment of myopia in vivo, the method comprising: a treatment step for applying the physical or chemical means to a myopia-induced model animal in which a signaling system associated with endoplasmic reticulum stress is activated; a measurement step for measuring a myopia-associated biomarker in the animal to which the physical or chemical treatment has been applied, after a lapse of a predetermined period of time after the treatment step; and a determination step for determining that the physical or chemical means is effective on the treatment of myopia in vivo when the following determination criterion is satisfied. The determination criterion: the amount of the change in the myopia-associated biomarker from a value before the activation of the signaling system associated with endoplasmic reticulum stress to the measured value is smaller than that in a myopia-induced model animal that has not been influenced by the physical or chemical means (i.e., a control).
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The purpose of the present invention is to provide sperm having high motility. The present invention is a composition for sperm treatment that contains medium for mesenchymal stem cells. This composition for sperm treatment is used as a sperm preparing solution, a sperm diluting solution, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a solution for improving sperm motility, or a solution for retaining sperm fertilizing capabilities. Additionally, the medium for mesenchymal stem cells contained in the composition for sperm treatment is preferably a serum-free medium.
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
The purpose of the present invention is to provide spermatozoa having high motility. The present invention is a composition for spermatozoa treatment that includes a mesenchymal stem cell culture supernatant. The composition for spermatozoa treatment of the present invention is used as a spermatozoa adjustment liquid, a spermatozoa dilution liquid, a spermatozoa preservation liquid, an artificial insemination solution, an in vitro fertilization solution, a solution for spermatozoa motility enhancement, or a solution for spermatozoa fertility retention. Furthermore, mesenchymal stem cells in the mesenchymal stem cell culture supernatant included in the composition for spermatozoa treatment are preferably derived from adipose tissue, derived from umbilical cord tissue, or derived from bone marrow tissue.
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
60.
PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION WHICH CONTAINS BENZOYL PEROXIDE
A pharmaceutical composition for external application which comprises (A) benzoyl peroxide and (B) at least one component selected from (B1) glycyrrhetinic acid and derivatives and salts thereof and (B2) allantoin does not undergo the decrease in viscosity over time and can be applied and spread smoothly on the skin.
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 31/4166 - 1,3-Diazoles ayant des groupes oxo liés directement à l'hétérocycle, p. ex. phénytoïne
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
The present invention relates to an ophthalmic composition for suppressing eye dryness, comprising at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 30,000 to 50,000 and a salt thereof.
A61K 31/737 - Polysaccharides sulfatés, p. ex. sulfate de chondroïtine, sulfate de dermatane
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/23 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine d'acides ayant un groupe carboxyle lié à une chaîne d'au moins sept atomes de carbone
A61K 31/4166 - 1,3-Diazoles ayant des groupes oxo liés directement à l'hétérocycle, p. ex. phénytoïne
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
62.
AGENT FOR INCREASING CD25-POSITIVE REGULATORY T CELLS IN KIDNEYS
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japon)
ROHTO PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Maruyama, Shoichi
Furuhashi, Kazuhiro
Tanaka, Akihito
Karasawa, Munetoshi
Takao, Yukinari
Abrégé
The present invention addresses the problem of providing a fundamental therapeutic method for renal diseases including glomerulonephritis such as IgA nephropathy. To solve this problem, the present invention pertains to an agent for increasing CD25-positive regulatory T cells in kidney, said agent comprising mesenchymal stem cells. The regulatory T cell-increasing agent of the present invention exerts a sufficient therapeutic effect even if further containing a cryopreservation liquid at a concentration of less than 5% (v/v).
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
Provided is an oily solid composition for external use with excellent stability. The oily solid composition for external use, containing: (A) an oily component having a melting point of 55°C or higher; (B) a polyhydric alcohol; and (C) an acrylic acid-based water-soluble polymer, is prepared.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61P 5/44 - GlucocorticoïdesMédicaments augmentant ou potentialisant l'activité des glucocorticoïdes
A first aspect of the present invention relates to an ophthalmic composition for suppressing the dryness of the eyes, the ophthalmic composition containing at least one component selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof. A second aspect of the present invention relates to an ophthalmic composition comprising at least one component selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof and at least one component selected from the group consisting of an antihistaminic agent, a zinc salt, tetrahydrozoline and salts thereof, hydroxyethyl cellulose and salts thereof and a polyvinyl-based polymeric compound. A third aspect of the present invention relates to an ophthalmic composition comprising at least one component selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof and menthol.
Provided is a water-in-oil composition for external use that contains ascorbic acid or a salt thereof. This prepared water-in-oil composition for external use contains: (A) at least one selected from the group consisting of ascorbic acid and an ascorbic acid salt; (B) propanediol; (C) an oil component; and (D) a silicone-based surfactant. This water-in-oil composition for external use has good stability.
A61K 8/894 - Polysiloxanes saturés, p. ex. diméthicone, phényl triméthicone, C24-C28 méthicone, stéaryl diméthicone modifiés par un groupe polyoxyalkylène, p. ex. cétyl diméthicone copolyol
A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention is a resin container having a multilayer structure including a first layer that comes into contact with liquid content and a second layer that is in contact with the first layer from an outer side of the first layer. The first layer includes a cyclic olefin copolymer and a linear low-density polyethylene resin, and the second layer includes a low-density polyethylene resin.
A61J 1/14 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques DétailsAccessoires à cet effet
B32B 27/08 - Produits stratifiés composés essentiellement de résine synthétique comme seul composant ou composant principal d'une couche adjacente à une autre couche d'une substance spécifique d'une résine synthétique d'une sorte différente
B32B 27/32 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyoléfines
An object of the present invention is to provide a new method for evaluating and/or screening an excellent healthcare material or pharmaceutical product based on a new concept. The present invention to solve the above object is a method for evaluating and/or screening a control agent for tissue morphology and/or tissue function, the method including: applying a test substance to a tissue or cell capable of expressing a mechanical stress signaling molecule; and evaluating expression, activity, or intracellular localization of the mechanical stress signaling molecule in the tissue or cell.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
70.
CLEANING COMPOSITION AND PRODUCTION METHOD FOR SAME
Provided is a cleaning composition that has excellent usability and makes it possible to suppress reduction in the enzymatic activity of a proteolytic enzyme or a lipolytic enzyme. According to the present invention, a cleaning composition contains (A) a higher fatty acid and/or a salt thereof, (B) a proteolytic enzyme and/or a lipolytic enzyme, (C) a polyalcohol, and (D) water. The (C) content is 25–60 mass% of the entire cleaning composition. The (D) content is 5–30 mass% of the entire cleaning composition. The cleaning composition contains glycerin and/or sorbitol as (C), and the glycerin and/or sorbitol content is 10–60 mass% of the entire cleaning composition.
Methods are described for treating a heart disease, comprising suspending c) mesenchymal stem cells in either a) a fibrinogen solution or b) a thrombin solution, thereby obtaining a cell suspension, and directly spraying the cell suspension on a disease site substantially at the same time with the other of a) the fibrinogen solution or b) the thrombin solution that is not used in the suspending.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
The present invention is a resin container in which an inner wall surface of a container body includes a cyclic olefin copolymer, and a diameter upstream of an outlet of the container body ranges from 0.5 mm to 8.0 mm.
The present invention provides a cleaning composition which has excellent formulation stability. A cleaning composition which contains (A) an N-acylamino acid salt, (B) an amphoteric surfactant and (C) a polyoxyethylene polyoxypropylene glycol. A cleaning composition which contains (A) an N-acylamino acid salt (excluding an N-acylalkyl taurine salt) and (a) an N-acylalkyl taurine salt, wherein: the mass ratio of the component (a) to the component (A), namely (a)/(A) is 0.5 or more; and the pH thereof is 4.0 to 5.0. A cleaning composition which contains (A) an N-acylamino acid salt (excluding an N-acylalkyl taurine salt), (a) an N-acylalkyl taurine salt and (B) an amphoteric surfactant, wherein: the mass ratio of the component (a) to the component (A), namely (a)/(A) is less than 0.5; and the pH thereof is 4.0 to 5.0.
A topical composition comprises (A) at least one polyhydric alcohol having a molecular weight of 100 to 200, and (B) at least one non-polymerizable cationic compound. The component (B) may be a compound containing a metal to be a divalent or higher cation in an aqueous solution, a basic amino acid, alkanol amine, or alkyl amine, and the component (A) may be glucose, sorbitol, fructose, xylitol, or erythritol.
A61Q 15/00 - Préparations contre la transpiration ou déodorants corporels
A61K 8/46 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant du soufre
The present invention relates to an ophthalmic composition for promoting tear secretion, the composition comprising 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile or a salt thereof.
The purpose of the present invention is to provide a prophylactic and/or therapeutic agent for diabetes that exerts excellent effects on diabetes occurring as a side effect of the administration of an immune checkpoint inhibitor and that can also achieve certain effects on many patients. The present invention pertains to a diabetes therapeutic agent containing mesenchymal stem cells. The prophylactic and/or therapeutic agent for diabetes according to the present invention is appropriately usable particularly for diabetes caused by an immune checkpoint inhibitor and diabetes caused by anti-PD-1 antibody or anti-PD-L1 antibody.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
Under these circumstances, the purpose of the present invention is to provide a novel anti-inflammatory agent and a novel therapeutic agent for neurological diseases using mesenchymal stem cells. The present invention pertains to mesenchymal stem cells characterized by hyperexpressing SIRT1. The present invention also involves mesenchymal stem cells characterized by hyperexpressing BDNF. Moreover, the present invention involves an anti-inflammatory agent and a therapeutic agent for neurological diseases comprising these cells.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
[Problem] To provide: a screening method for searching for an ingredient that inhibits PERK (PKPK-like endoplasmic reticulum kinase) pathway and/or ATF6 (activating transcription factor 6) pathway; and eyedrops and a composition comprising an active ingredient that inhibits myopia progression in children without inhibiting normal ocular growth (emmetropization), said active ingredient being obtained by the aforesaid screening method. [Solution] Eyedrops for inhibiting myopia progression in children, said eyedrops comprising, as an active ingredient, an inhibitor of PERK pathway and/or ATF6 pathway. A screening method for an inhibitor of myopia progression in children, said screening method comprising a step for bringing candidate substances into contact with eye-derived cells and a step for selecting a candidate substance using changes in a protein and/or a gene in PERK and/or ATF6 signaling pathways in the cells as an indicator.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
81.
EYEDROPS FOR TREATING SCLERAL THINNING AND SCREENING METHOD FOR THERAPEUTIC AGENT OF SCLERAL THINNING
[Problem] To provide: a screening method for searching for an ingredient that inhibits and treats scleral thinning; and eyedrops that comprise an active ingredient, said active ingredient being obtained by the screening method, and thus that can inhibit excessive scleral thinning to thereby treat posterior ocular disease associated with scleral thinning. [Solution] Eyedrops that comprise, as an active ingredient, an ingredient capable of simultaneously inhibiting PERK pathway and/or ATF6 pathway. A screening method for an ingredient capable of simultaneously inhibiting PERK pathway and/or ATF6 pathway, said screening method comprising a step for bringing candidate substances into contact with eye-derived cells and a step for selecting a candidate substance using effects on scleral thinning in the cells as an indicator.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters.
Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters.
Provided is a composition for external use on skin, which can be packed in a container easily in the production thereof and is configured such that a proper amount can be discharged upon the application onto the skin. A composition for external use on skin is produced, which has good wettability on a polyolefin resin. The composition for external use on skin is prepared, the composition for external use on skin comprising (A) at least one component selected from the group consisting of ascorbic acid and an ascorbic acid salt and (B) a lower alcohol, and the composition for external use on skin being packed in a container in which a portion or the whole of a face that comes into contact with the composition for external use on skin comprises a resin containing a polyolefin.
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japon)
LINK GENOMICS, INC. (Japon)
ROHTO PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Katabuchi,hidetaka
Honda,ritsuo
Niwa,shinichiro
Kitadai,eri
Hayashi,hidemi
Arita,harumasa
Abrégé
The purpose of the present invention is to provide: a composition for ameliorating an unpleasant state related to menstruation, the composition being effective for an unpleasant feeling felt by females from first menstruation to menopause, in particular, a very unpleasant feeling felt by young females, having anti-EMT activity, and being sufficiently experienced as foodstuff; and a functional food containing said composition. According to the present invention, a composition, which is for ameliorating an unpleasant state caused by menstruation and contains at least one selected from the group consisting of black rice, cherry, and extracts thereof, is prepared.
A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p. ex. bambou, blé ou canne à sucre
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A61K 36/736 - Prunus, p. ex. prune, cerise, pêche, abricot ou amande
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/08 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des nausées, du mal des transports ou des vertigesAntiémétiques
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
88.
Topical composition containing ascorbic acid and/or salt thereof
Provided is a very stable topical composition. A topical composition is prepared that contains (A) from 1 to 40% by mass of at least one type selected from the group consisting of ascorbic acid and salts of ascorbic acid; (B) at least 20% by mass of a diol having three carbon atoms; (C) at least one type selected from the group consisting of tocopherol, salts of tocopherol, and derivatives of tocopherol; and (D) water, wherein the mass ratio of component (D) to component (A) is from 0.5 to 5.0 and the topical composition includes less than 20% by mass of glycol ether.
The present invention relates to an aqueous composition containing (A) delgocitinib or a salt thereof and (B) at least one substance selected from the group consisting of citric acid, phosphoric acid, and salts of these.
The present invention relates to an aqueous composition containing (A) delgocitinib or a salt thereof and (B) at least one substance selected from the group consisting of edetic acid, creatinine, and salts of these.
The present invention relates to an aqueous composition containing (A) delgocitinib or a salt thereof and (B) at least one substance selected from the group consisting of citric acid, phosphoric acid, and salts of these.
The present invention relates to an aqueous composition containing (A) delgocitinib or a salt thereof and (B) at least one substance selected from the group consisting of edetic acid, creatinine, and salts of these.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
In-vitro diagnostic drugs; eye wash bactericides; eye
ointments; contact lens cleaning preparations;
pharmaceutical preparations and other preparations for
destroying vermin, fungicides, herbicides; reagent paper for
medical purposes; collyrium; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies; dietary
supplements (excluding those belonging to drugs); oiled
paper for medical purposes; adhesive tapes for medical
purposes; drug delivery agents in the form of edible wafers
for wrapping powdered pharmaceuticals; gauze for dressings;
empty capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; dietary
supplements for humans; semen for artificial insemination.
The purpose of the present invention is to provide a composition which, even if the ethanol content is relatively high, suppresses ethanol-induced drying that could occur upon application onto the skin, and which, when used, gives a good feeling. Provided is a composition for external use, which contains (A) ethanol and (B) at least one selected from the group consisting of erythritol, sorbitol, and xylitol, and has an ethanol (A) content of 32 to 85 mass%.
A61Q 17/00 - Préparations protectricesPréparations employées en contact direct avec la peau pour protéger des influences extérieures, p. ex. des rayons du soleil, des rayons X ou d'autres rayons nuisibles, des matériaux corrosifs, des bactéries ou des piqûres d'insectes
A61Q 19/00 - Préparations pour les soins de la peau
95.
COMPOSITION FOR EXTERNAL USE ON SKIN CONTAINING ASCORBIC ACID AND/OR SALT THEREOF
Provided is a composition for external use on the skin which is excellent in terms of use feeling and appearance. The purpose of the present invention is to provide a composition for external use on the skin which has satisfactory use feeling, that is, good slipperiness, and is reduced in coloration. The composition for external use on the skin comprises (A) at least one compound selected from the group consisting of ascorbic acid and salts of ascorbic acid, (B) at least one compound selected from the group consisting of salicylic acid, salts of salicylic acid, and derivatives of salicylic acid, and (C) a diol having three carbon atoms, the content of which is 1-50 mass%.
A61K 8/368 - Acides carboxyliquesLeurs sels ou anhydrides dans lesquels le groupe carboxyle est directement lié aux atomes de carbone du cycle aromatique
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
In-vitro diagnostic drugs; eye wash bactericides; eye
ointments; contact lens cleaning preparations;
pharmaceutical preparations and other preparations for
destroying vermin, fungicides, herbicides; reagent paper for
medical purposes; collyrium; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies; dietary
supplements (excluding those belonging to drugs); oiled
paper for medical purposes; adhesive tapes for medical
purposes; drug delivery agents in the form of edible wafers
for wrapping powdered pharmaceuticals; gauze for dressings;
empty capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; dietary
supplements for humans; semen for artificial insemination.
The present invention provides an oil-in-water cosmetic composition. The present invention is an oil-in-water cosmetic composition which contains (A) a benzotriazole type ultraviolet absorbent, (B) one or more substances that are selected from the group consisting of silicone waxes and silica, and (C) water. With respect to this oil-in-water cosmetic composition, the average particle diameter of silica in the component (B) is 1 μm or more; and the content of the component (C) based on the total amount of this oil-in-water cosmetic composition is 50% by mass or more.
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61K 8/895 - Polysiloxanes contenant du silicium lié à un groupe aliphatique non saturé, p. ex. vinyl diméthicone
The present invention relates to an ophthalmic composition for suppressing drying of the eyes, the composition containing at least one substance selected from the group consisting of chondroitin sulfates having weight-average molecular weights of 30,000 to 50,000 and salts thereof.
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japon)
ROHTO PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Maruyama Shoichi
Furuhashi Kazuhiro
Tanaka Akihito
Karasawa Munetoshi
Takao Yukinari
Abrégé
The present invention addresses the problem of providing a fundamental therapeutic method for kidney diseases including glomerulonephritis such as IgA nephropathy. To solve this problem, the present invention pertains to an agent for increasing CD25-positive regulatory T cells in kidney, said agent comprising mesenchymal stem cells. The regulatory T cell-increasing agent of the present invention exerts a sufficient therapeutic effect even if further containing a cryopreservation liquid at a concentration of less than 5% (v/v).
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
The purpose of the present invention is to provide mesenchymal stem cells that have exceptional cell adhesiveness, do not require serum medium, and have an adequate cell proliferation rate. The present invention is mesenchymal stem cells characterized in that the amount of granulocyte colony stimulating factor (G-CSF) produced is enhanced. The present invention also includes mesenchymal stem cells characterized in that the amount of at least one selected from the group consisting of eotaxin, fractalkine, GRO, MCP-3, and VEGF produced is enhanced.
